Article
Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 15 Sept 2005
Arnedo-Valero M, Garcia F, Gil C, Guila T, Fumero E, Castro P, Blanco J L, Miró J M, Pumarola T, Gatell J M
Abstract excerpt
BACKGROUND: Structured treatment interruption (STI) may allow viral replication in the presence of decreased plasma drug levels, with risk of selection of resistance mutations. METHODS: For patients recruited for an STI study, genotypic resistance testing was performed at baseline (before receipt of any treatment), immediately before the STI, and 2 weeks after each interuption of therapy. RESULTS: During 20 (18%)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.